Abstract Adoptive immunotherapy (AIT) using ex vivoexpanded HER-2/neu-speciWc T cells has shown initial promising results against disseminated tumor cells in the bone marrow. However, it has failed to promote objective responses against primary tumors. We report for the Wrst time that alternating gamma chain cytokines (IL-2, IL-7 and IL-15) ex vivo can expand the neu-speciWc lymphocytes that can kill breast tumors in vitro. However, the antitumor eYcacy of these neu-speciWc T cells was compromised by the increased levels of myeloid-derived suppressor cells (MDSC) during the premalignant stage in FVBN202 transgenic mouse model of breast carcinoma. Combination of AIT with the depletion of MDSC, in vivo, resulted in the regression of neu positive primary tumors. Importantly, neu-speciWc antibody responses were restored only when AIT was combined with the depletion of MDSC. In vitro studies determined that MDSC caused inhibition of T cell proliferation in a contact-dependent manner. Together, these results suggest that combination of AIT with depletion or inhibition of MDSC could lead to the regression of mammary tumors.
Introduction
To date, several vaccination strategies have been successfully employed to induce tumor-speciWc CD8+ and CD4+ T cell responses. However, such immunological responses have rarely been robust enough to achieve tumor regression [7, 48] . To overcome this obstacle by increasing the frequency of tumor-speciWc T cells, adoptive immunotherapy (AIT) treatments with eVector cells activated and expanded ex vivo have been introduced and evaluated against a variety of cancers [8, 36] . Although AIT trials have exhibited partial eVects in the case of melanoma and metastatic breast carcinoma, these therapies failed to exhibit objective responses against HER-2/neu positive breast tumors [2, 29] . Among a variety of approaches for the expansion of anti-tumor T cells, ex vivo, stimulation of T cells with bryostatin-1 (B) and ionomycin (I) has been shown to be promising in speciWcally activating anti-tumor eVector T cells by mimicking signals through the T cell receptor, thus causing the expansion of tumor-speciWc eVector T cells in the absence of the nominal antigen, ex vivo [6] . T cells activated in this manner and expanded in the presence of IL-2 were able to cause regression of MCA-105 pulmonary metastasis in vivo, as well as of established 4T07 mammary tumors transfected with IL-2 [5, 41] . However, IL-2 expansion may lead to the induction of regulatory T cells (T regs) and cause activation-induced cell death in T cells [20, 33, 47] . Alternatively, the gamma chain cytokines IL-7 and IL-15 are attractive candidates for AIT because of their role in the maintenance and proliferation of eVector and memory T cells. IL-7 has been implicated as a pro-survival cytokine for early memory CD8+ T cell selection and maintenance, while IL-15 can protect eVector CD8 + T cells from apoptosis, as well as augment their cytotoxic eVects [21, 22, 30, 38, 40, 43] . Additionally, unlike IL-2, IL-7 and IL-15 do not cause activation-induced cell death, nor are they needed for the maintenance of T regs [42] .
One major obstacle hindering the clinical response of cancer immunotherapy is the presence of suppressor cells. In tumor-bearing hosts, myeloid-derived suppressor cells (MDSC) have emerged as a signiWcant mediator of immune suppression in various types of cancer. For example, MDSC accumulate in several mouse models of cancer, including the MCA-26 colon carcinoma, the 4T1 mammary carcinoma, and the neu-overexpressing mouse mammary carcinoma (MMC) [4, 19, 27] . In humans, the presence of MDSC has been associated with head and neck cancer, renal cell carcinoma, and breast cancer [10, 32, 45] . Importantly, increased levels of circulating MDSC have recently been correlated with disease stage and extensive metastatic tumor burden in patients with breast cancer [10] . It was reported that MDSC accumulate in response to tumor-derived soluble factors VEGF, GM-CSF, and M-CSF [14, 16] and inhibit anti-tumor T cell responses, possibly through the production of soluble factors nitric oxide, arginase-1, reactive oxygen species, and inhibitory cytokines such as IL-10 [3, 28, 32, 35, 46] . In particular, arginine depletion and the production of reactive oxygen species can result in downregulation of the TCR zeta chain as well as T cell arrest in the G 0 phase of the cell cycle [13, 14] and impairment of IL-2 signaling [28] , respectively. However, the role of MDSC in inhibiting adoptively transferred tumor-speciWc eVector T cells has not yet been clearly deWned.
The FVBN202 mouse model of spontaneously arising mammary carcinomas provides a clinically relevant model for investigating the immunotherapy of HER2/neu positive mammary tumors. These mice develop mammary carcinomas within 4-12 months of age due to the overexpression of the rat neu oncogene in their mammary glands under the regulation of the mouse mammary tumor virus (MMTV) promoter [18] . In these mice, atypical mammary hyperplasia develops prior to the occurrence of spontaneous mammary tumors and is accompanied by an increase in MDSC in the peripheral blood and spleen of FVBN202 mice during the premalignant stage, rendering animals resistant to neu-targeted immunotherapy [19, 26] . Furthermore, inoculation of MMC into FVBN202 mice causes a rapid and pronounced increase in MDSC [19] . In contrast, parental FVB mice do not express the rat neu oncogene and therefore are able to generate a robust immune response against challenge with neu-expressing MMC. These mice subsequently reject MMC, thus generating a pool of T cells with proven eVectiveness against these tumors. These T cells derived from parental FVB mice are therefore ideal candidates for evaluating the eYcacy of protocols for expanding neu-speciWc T cells in the absence of the nominal antigen, ex vivo. In addition, their FVBN202 transgenic counterpart provides an ideal model in which the eVects of increased endogenous MDSC on adoptively transferred eVector T cells can be evaluated. This study addresses, for the Wrst time, the consequences of increased MDSC on the eYcacy of AIT in the FVBN202 mouse model of breast carcinoma, as well as the novel Wnding of a restored neu-speciWc antibody response following the depletion of MDSC, in vivo. These Wndings suggest that AIT in breast cancer patients may be improved if it is combined with the inhibition or depletion of MDSC and that MDSC may also play a role in the suppression of B cell responses.
Materials and methods

Mouse model
Parental FVB (Jackson Laboratories) and FVBN202-transgenic female mice (Charles Riveer Laboratories) were used between 6 and 10 weeks of age throughout these studies. FVBN202 mice overexpress an unactivated rat neu transgene under the regulation of the MMTV promoter [18] . These mice develop premalignant mammary hyperplasia similar to ductal carcinoma in situ (DCIS) prior to the development of spontaneous carcinoma [24] . These studies have been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University.
Tumor cell lines
The MMC cell line was established from a spontaneous tumor harvested from an FVBN202 transgenic mouse as previously described [23] . The antigen negative variant (ANV) cell line was derived from a relapsed MMC tumor in the FVB strain as previously described and is characterized by a loss of neu expression [23] . Both cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Mice were challenged with 3 £ 10 6 MMC cells i.d. where indicated.
Recombinant neu protein
The cDNAs coding for sub-domain II of the extracellular domain of rat neu (ECDII:187-332 aa) were ampliWed by PCR using the following primers: 5Ј-GTGGAATTCACCA ATCGTTCCCGGGCC-3Ј(sense) and 5Ј-TCAAGCTTCA CAACGCTGTGTTCC-3Ј (antisense). Restriction sites are underlined. The resulting fragments were cleaved with EcoR I and Hind III and ligated into the EcoRI-Hind III fragment of pRSET A to generate the constructs. The recombinant proteins were expressed in E. coli using IPTG as an inducer of expression. PuriWcation of His-tagged protein was performed under denaturing conditions using the Guanidinium Lysis BuVer. After elution, proteins were dialyzed in 20 mM Tris, pH 9.0 overnight (4°C). Dialyzed proteins were concentrated using 10,000 MW cut-oV columns (Viva Spin), Wlter-sterilized and protein concentration was determined using Bradford assay.
Flow cytometry
Flow cytometry analysis was performed as previously described by our group [23] . BrieXy, splenocytes were homogenized into a single cell suspension and 10 6 cells were aliquoted into each sample tube. Non-speciWc binding to Fc receptors was blocked with anti-CD16/CD32 antibody (Biolegend) for 20 min on ice. Cells were stained with surface antibodies towards various markers and incubated on ice in the dark for 20 min. Cells were washed twice and Wxed with 1% paraformaldehyde or were washed again in 1X Annexin V buVer (BD Pharmingen) and the Annexin V staining protocol was followed. Samples were run on a Beckman Coulter FC 500 and analyzed using Summit version 4.3 software.
Cytotoxicity assay
Neu-speciWc eVector lymphocytes were cultured with MMC at 10:1 and 20:1 E:T ratios in complete medium (RPMI-1640 supplemented with 100 U/mL penicillin, 100 g/mL streptomycin, and 10% FBS) and 20 U/mL recombinant IL-2 (Peprotech) in six well culture dishes. After 24 h, 3 mL fresh media was added to the existing 3 mL of media. After 48 h, cells were harvested and stained for neu (anti-c-ErbB2/c-Neu, Calbiochem), Annexin V and PI according to the manufacturer's protocol (BD Pharmingen). Flow cytometry was used to analyze the viability of neu positive cells.
IFN-ELISA
Neu-speciWc eVector lymphocytes were cultured in complete medium at a 10:1 ratio with irradiated MMC cells or ANV cells (15,000 rad) for 24 h. Supernatants were collected and stored at ¡80°C until used. IFN-was detected using a Mouse IFN-ELISA Set (BD Pharmingen) according to the manufacturer's protocol. Results are reported as the mean values of duplicate wells.
Expansion of eVector T cells from FVB mice FVB parental mice were inoculated with 5 £ 10 6 MMC cells and splenocytes harvested after 20-25 days. Splenocytes (10 6 cells/mL) were stimulated in complete medium containing 15% FBS with bryostatin-1 (5 nM) and ionomycin (1 M) along with 80 U/mL of IL-2 (Peprotech) for 16 h. Cells were washed three times and cultured at 10 6 cells/mL in complete medium with 40 U/mL IL-2 and media was changed every other day for a total of 7 days. Cells expanded with alternating gamma chain cytokines were cultured on day 1 with 10 ng/mL IL-7 and 10 ng/mL IL-15 (Peprotech). On day 2, 40 U/mL of IL-2 was added. Medium was changed on days 3 and 5, each time culturing with 10 ng/mL each of IL-7 and IL-15 and injections were done on day 7. Aliquots of cells were taken at indicated time points and samples were stained with combinations of the following antibodies and assessed by Xow cytometry: FITC-CD25, FITC-CD62L, FITC-CD8, PE-CD44, PE-CD69, PE-CD8, PE/Cy5-CD4, PE/Cy5-CD8, PE/Cy5-CD69 from Biolegend and PE-CD25, PE-CD4 from BD Pharmingen. All antibodies were used at the manufacturer's recommended concentration.
Adoptive immunotherapy
Twenty-four hours prior to AIT, FVBN202 mice were treated with Cyclophosphamide (CYP, 100 mg/kg) by i.p. injection in order to induce lymphopenia. Mice were challenged i.d. with 3 £ 10 6 MMC cells and then received 70 £ 10 6 T cells by tail vein injection later the same day. Tumor growth was monitored by digital caliper and tumor volumes were calculated by: V(volume) = [L(length) £ W(width) 2 ]/2. Blood was collected from the orbital sinus periodically to determine antibody responses and levels of CD11b + Gr1+ cells by Xow cytometry. At the termination of the experiment, splenocytes were harvested and stained using the same antibodies as indicated above.
Depletion of MDSC in vivo
Monoclonal antibody against the surface antigen Gr1 was puriWed from the RB6-8C5 hybridoma by collecting supernatant from the CELLine CL 1,000 Xask (IBS Integra Biosciences) according to the user manual. Supernatant was stored at ¡80°C until IgG puriWcation using a MEP-Hypercell column. Where indicated, mice were injected i.p. with 250 g of anti-Gr1 antibody for a total of 6 times at 3-day intervals, followed by a Wnal injection of 200 g on day 25 . Depletion was veriWed by Xow cytometry of the peripheral blood for the CD11b and Gr1 surface markers. The dose of anti-Gr1 antibody was proven completely eVective in mice bearing MMC tumors that were 25 mm 3 or smaller.
Isolation of MDSC in vitro
Gr1+ cells were isolated using an EasySep PE Selection kit from StemCell Technologies. The protocol from the manufacturer was followed using splenocytes homogenized from MMC tumor-bearing FVBN202 mice labeled with 2 g/mL of PE-Gr1 or PE-CD11b antibody from Biolegend. Purity of Gr1 + cells was conWrmed by Xow cytometry and was >90%.
In vitro T cell proliferation and BrdU labeling T cell stimulations were done in 96 well plates. Plates were coated with 10 g/mL of anti-CD3 (BD Pharmingen) and were washed three times with PBS after 24 h to remove any unbound antibody. Splenocytes (10 6 cells/ mL in complete media), were labeled by adding 10 M BrdU (BD Pharmingen) directly to the culture medium. Soluble anti-CD28 antibody (BD Pharmingen) was also added to the culture medium at 1 g/mL. Cells were plated at 2 £ 10 5 cells/well and were allowed to proliferate for 72 h at 37°C, 5% CO 2 . Staining for BrdU was done following the protocol from the manufacturer (BD Pharmingen) using the FITC-conjugated anti-BrdU Xow kit. Where indicated, MDSC were depleted from the splenocyte populations using the PE Selection protocol above with either PE-Gr1 or PE-CD11b antibodies (Biolegend). Isolated MDSC were added to wells where indicated at a 1:2 MDSC to splenocyte ratio either in the absence of a transwell insert, or in the top chamber of a transwell insert with 8.0 m pore (Corning Life Sciences).
ELISA
Blood was collected from mice via the retro-orbital sinus, allowed to sit at room temperature for 10 min, and then spun for 10 min at 10,000 rpm. Serum was harvested and stored at ¡80°C until used. For measuring the antibody response against neu, 96 well plates were coated with 10 g/mL of the ECDII and incubated overnight at 4°C. Plates were washed with PBS + 0.05% Tween-20 and blocked with 2% skim milk for 1 h. After washing, Wvefold serial dilutions of the sera were added (100 L/well) and incubated for 2 h at room temperature. Horse-radishperoxidase (HRP)-conjugated anti-mouse IgG1 from Caltag was added at a 1:2,000 dilution for 1 h. Plates were washed and reactions developed by adding 100 L/well of the TMB Microwell peroxidase substrate (Kierkegaard and Perry). The reaction was stopped with 2 M H 2 SO 4 , and the OD read at 450 nm. Mean antibody titers were then calculated.
Results
Bryostatin-1/Ionomycin (B/I) stimulation followed by IL-2 expansion generates highly activated neu-speciWc eVector T cells Since parental FVB mice recognize the rat neu protein as a foreign antigen and are subsequently able to reject MMC, whereas FVBN202 mice often tolerate neu protein and are unable to reject MMC, FVB mice were used as donors for AIT transfers into FVBN202 recipients in these studies. Since B/I selectively activates eVector/memory T cells regardless of their antigen speciWcity [41] , we sensitized FVB mice with MMC cells in order to increase the pool of neu-speciWc eVector/memory T cells prior to T cell harvest for B/I activation ex vivo. We Wrst compared the populations of CD4+ and CD8+ T cells from these donors immediately after harvest, after activation with B/I, and after a 7-day expansion with IL-2. Representative data from duplicate experiments are presented in Fig. 1a . FVB donor splenocytes contained 35 and 9% CD4+ and CD8+ T cells, respectively. These populations were similar immediately after B/I activation (27 and 12% CD4+ and CD8+, respectively) but were greatly increased after 7 days of culture with IL-2 (55 and 32% CD4+ and CD8+, respectively). Furthermore, IL-2 treatment increased the absolute number of viable T cells by 9.5-fold over the cell number that was cultured after B/I expansion (Fig. 1b) . Annexin V+ CD4+ populations remained nearly constant during ex vivo expansion, starting at 20% on day 0 compared with 24% after B/I activation and cytokine treatment (Fig. 1c) . The CD8+ T cells, however, showed a marked increase in Annexin V+ staining from day 0 to 7, with the fresh splenocytes being only 13% Annexin V+, while the post-B/I and post-cytokine values were 23 and 54%, respectively (Fig. 1c) .
In order to determine T cell phenotypes, Xow cytometry was performed for memory T cells (CD44+ CD62L+) and eVector T cells (CD44+ CD62L¡), as well as for the activation marker CD25, and the very early activation marker CD69, in both the CD4+ and CD8+ populations (Fig. 1d) . As expected, B/I activation greatly increased the eVector phenotype in the CD4+ population from 16 to 79% and in the CD8+ population from 5 to 66% while naïve (CD44¡ CD62L+) and memory (CD44+ CD62L+) CD4+ and CD8+ T cells were greatly decreased (Fig. 1d) . After IL-2-induced expansion, both CD4+ and CD8+ T cells showed a marked increase in CD44+ CD62L+ memory T cells (74 and 58% in the CD4+ and CD8+ compartments, respectively), while maintaining increased levels of CD44+ CD62L¡ eVector T cells compared to pre-B/I treatment (16 vs. 22% and 5 vs. 38%, respectively). Additionally, the expression of CD25 on CD4+ and CD8+ T cells was markedly increased to over 80% in both cases after B/I activation, and increased to over 90% in both populations after IL-2 expansion (Fig.  1e) . The very early activation marker, CD69, was greatly increased from about 0.1-0.2% in fresh splenocytes to 87% in CD4+ T cells and 93% in CD8+ T cells after B/I activation. This value, however, dropped again after a 7-day culture with IL-2, with 0.8% CD69 expression in CD4+ T cells, and, notably, 3% remaining in the CD8+ T cells. However, most cells retained a late eVector phenotype (CD44+ CD69¡) on day 7 (Fig. 1f) .
To conWrm anti-tumor eYcacy in vitro, T cells derived from MMC sensitized FVB mice prior to (Pre-B/I) or after a 7-day ex vivo expansion (post-cytokine) were co-cultured with MMC target cells (E:T ratio of 10:1) for 48 h followed by staining with antibodies directed towards neu, Annexin V, and PI. Control wells were seeded with MMC in the absence of T cells (Medium) (Fig. 2a) . Gating on neu positive cells and analyzing the percentages of Annexin V and PI positive cells allowed for the determination of speciWc killing of the neu positive MMC cells by T cells. Viability of MMC in the absence of T cells was 86% (Annexin V and PI negative) while it dropped to 44% in the presence of the freshly isolated T cells (Pre-B/I). Viability of MMC was further decreased to 27% when cultured with B/I-activated, (Fig. 2a) Absolute numbers of viable MMC also reXect increased anti-tumor eYcacy of B/I-activated, IL-2-expanded T cells compared to freshly isolated T cells (P = 0.026) (Fig. 2b) . No killing was detected against the neu negative tumor variant, as determined by trypan blue exclusion (data not shown).
Increased anti-tumor eYcacy of the B/I-activated, IL-2-expanded T cells was due to an increased frequency of the neu-speciWc T cells compared to the freshly isolated T cells, as determined by IFN-ELISA (data not shown).
T cell expansion using an alternating gamma chain cytokine regimen increases T cell expansion and viability as well as anti-tumor eYcacy in vitro
In order to select the best method of T cell expansion for AIT we sought to determine if expansion of T cells in the presence of alternating gamma chain cytokines may have advantages over expansion in the presence of IL-2 alone in terms of the expansion rates, viability, phenotype, and antitumor eYcacy in vitro. Therefore, we expanded T cells using alternating gamma chain cytokines, i.e., adding a combination of IL-7 and IL-15 (10 ng/mL) on days 1, 3, and 5 with a one-time "pulse" of IL-2 (40 U/mL) on the second day. This type of expansion increased the percentage of CD8+ T cells (32% in Fig. 1a vs. 47% in Fig. 3a) and showed an 11-fold expansion in overall viable T cell number as compared to a 9.5-fold expansion with IL-2 treatment (Fig. 1b vs. 3b) . Alternating gamma chain cytokines also greatly enhanced the viability of T cells on day 7 of culture when compared to expansion with IL-2 alone (Fig. 3c shows 13% Annexin V+ CD4+ T cells and 11% Annexin V+ CD8+ T cells compared with 24% Annexin V+ CD4+ T cells and 54% Annexin V+ CD8+ T cells in Fig. 1c ). Of note, there were more CD44+ CD62L¡ eVector T cells in both the CD4+ and CD8+ compartments after expansion using alternating gamma chain cytokines as compared to expansion with IL-2 alone (33 vs. 22% CD4+ T cells and 48 vs. 38% CD8+ T cells, Figs. 1d, 3d) . While the percentage of CD4+ CD25+ T cells and CD4+ CD69+ T cells remained unchanged, CD8+ CD25+ T cells decreased from 92 to 69% and CD8+ CD69+ T cells decreased from 3 to 0.3% in comparing the IL-2-expanded T cells with alternating cytokine-expanded T cells, respectively (Figs. 1d, 3d) . The cytotoxic eVect of T cells against MMC, in vitro, was also greater using alternating gamma chain cytokines compared to that using IL-2 (27% viable MMC in Fig. 2a vs. 14% viable MMC in Fig. 3e ). Absolute numbers of viable MMC also reXects a slight increase in anti-tumor eYcacy of B/I-activated, alternating cytokineexpanded T cells compared to IL-2-expanded T cells (0.5 £ 10 6 in Fig. 2b vs. 0.4 £ 10 6 in Fig. 3e ). Cells expanded in alternating cytokines also exhibited a strong IFN-response when stimulated with irradiated neu positive MMC (15,000 rad), but not with neu-negative ANV cells (P = 0.006), thus conWrming the neu speciWcity of these cells (Fig. 3f ).
Adoptive transfer of T cell subsets expanded ex vivo with alternating gamma chain cytokines inhibits tumor growth when combined with the depletion of MDSC in vivo
We hypothesized that an immunosuppressive environment characterized by a drastic increase in CD11b+ Gr1+ MDSC in the peripheral blood and spleens of FVBN202 mice would inhibit the anti-tumor eYcacy of neu-speciWc T cells prepared from MMC sensitized FVB donor mice. To test this hypothesis, FVB mice were inoculated with MMC (5 £ 10 6 cells/mouse) and donor splenocytes were prepared 21 days after tumor challenge, when animals had completely rejected MMC. T cells were activated with B/I and were then expanded in the presence of alternating gamma chain cytokines as described above (Fig. 3) . All FVBN202 mice were treated with i.p. injection of CYP (100 mg/kg) in order to create lymphopenia. Flow cytometry of the peripheral blood before, and 24 h after, CYP injection, showed no eVect of this drug on the CD11b+ Gr1+ population. FVBN202 mice were challenged with MMC (3 £ 10 6 ) 24 h after CYP treatment. MMC-challenged mice then received no treatment, the alternating gamma chain cytokineexpanded T cells alone (i.v. injection of 70 £ 10 6 lymphocytes/mouse), or AIT combined with the depletion of MDSC by i.p. injection of an anti-Gr1 antibody starting 6 days after tumor inoculation and continuing every 3 days for a total of six injections, followed by a Wnal injection of 200 g on day 25 (Fig. 4a) . AIT alone oVered no protection against MMC (Fig. 4a) . However, the in vivo depletion of MDSC improved the eYcacy of AIT and caused signiWcant tumor inhibition (P = 0.001 for week 4 and P = 0.0003 for week 5). The eYcacy of MDSC depletion was above 98% 9 days after tumor challenge (data not shown). Flow cytometry analysis of blood collected from each group 24 days after the tumor challenge showed that the group receiving Gr1 depletions had a signiWcantly reduced percentage of MDSC (Fig. 4b) . However, it is noteworthy that 38% of the granulocytes were still CD11b + Gr1 + at this time, a problem that we believe to be caused by slightly increased tumor burden in these mice leading to increased recruitment of MDSC (Fig. 4b) . Our preliminary studies showed that the optimal dose of anti-Gr1 antibody was eVective in depleting MDSC, however, we were not able to increase the frequency of antibody injections because of toxicity of the antibody (data not shown). Flow cytometry analysis of MDSC levels in the blood on day 35 (10 days after the last injection of anti-Gr1 antibody) showed that levels of MDSC were fully replenished in the Gr1 depletion group (data not shown). AIT using either CD4 + or CD8+ T cells alone, as well as the administration of anti-Gr1 antibody alone, did not cause tumor inhibition (data not shown).
Since the ECD-speciWc antibody response is also involved in the protection against neu positive mammary tumors [11, 12, 25] , we sought to determine whether FVBN202 mice mounted antibody responses against the ECD following AIT. Serum taken from mice receiving adoptive transfer of T cells expanded with alternating gamma chain cytokines with and without the in vivo depletion of MDSC, along with control mice, indicated that only mice that were depleted of Gr1+ cells were able to mount an antibody response against the ECD (P = 0.006) (Fig. 4c) .
The presence of MDSC inhibits CD3/CD28-induced proliferation of T cells in vitro in a contact-dependent manner
To determine the mechanisms by which MDSC suppress anti-tumor immune responses, splenocytes were isolated from MMC tumor-bearing and tumor-free FVBN202 mice. The tumor-bearing mice had a large inXux in MDSC in their spleens as compared to tumor-free mice [19] . Splenocytes were labeled with the thymidine analog BrdU and stimulated with antibodies against CD3 (10 g/mL, plate-bound) and CD28 (1 g/mL, soluble), or were left unstimulated to serve as a control. After 3 days, cells were stained using anti-CD4 and anti-CD8 antibodies and analyzed for BrdU uptake by Xow cytometry. We found higher proliferation of CD4+ T cells from tumor-free mice compared to those from tumorbearing animals (Fig. 5a, 91 vs. 59%, P = 0.002). The same trend was seen for CD8+ T cells (Fig. 5a, 93 vs. 70%). Similar trends were detected while analyzing absolute numbers of CD4+ and CD8+ T cells (Fig. 5b) . Fig. 5b shows that the average number of BrdU+ CD4+ and BrdU+ CD8+ T cells from tumor-free mice is 3.3-fold higher than that of BrdU+ CD4+ and BrdU+ CD8+ T cells from tumor-bearing mice (P = 0.003 for CD4+ and P = 0.0004 for CD8+ T cells). Using lymphocytes derived from FVB donors we also found similar patterns of the MDSC-mediated suppression of T cell proliferation in vitro (data not shown). To conWrm that the suppression of T cell proliferation in FVBN202 splenocytes was caused by the presence of elevated MDSC, we depleted MDSC in vitro, from the splenocytes of the tumor-bearing animals. As seen in Fig. 5a , the depletion of MDSC (tumorbearing-MDSC) signiWcantly restored the proliferative responses of both CD4+ (87% BrdU+) and CD8+ (92% BrdU+) T cells over those seen in total splenocytes (P = 0.028 for CD4+ and P = 0.009 for CD8+ T cells). Similar trends were found while comparing the absolute numbers of CD4+ and CD8+ T cells, showing a 3.1-fold increase in proliferation in the CD4+ population (P = 0.027) and 2.5-fold increase in the CD8+ population (P = 0.012) over total splenocytes from tumor-bearing mice (Fig. 5b) . To determine if the anti-proliferative eVects of MDSC on T cells were contact-dependent, CD11b+ cells were depleted from the splenocytes of tumor-bearing and tumor-free mice and equal numbers of lymphocytes (5 £ 10 5 ) were stimulated in the lower chamber of a plate containing a Transwell insert. CD11b+ cells depleted from tumor-bearing mice were then added to the lower chamber of the plate, or were added to the top chamber of the Transwell insert, where they were separated from the lymphocytes by an 8.0 m pore. Staining for BrdU incorporation on day 3 showed potent inhibition when CD11b+ cells were added back to the cultures, but only in the absence of a Transwell insert (Fig. 5c ). There was a total lack of inhibition observed when CD11b+ cells were separated from the T cells by a transwell insert (Fig. 5c) . Similar trends were detected while analyzing the absolute numbers of CD4+ and CD8+ T cells (data not shown). 
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Discussion
The adoptive transfer of tumor-speciWc T cells that have been activated and expanded in vitro is a promising means of systemically treating residual cancers after resection of the primary tumor. The presence of immune suppressor cells has, however, become a substantial obstacle to the success of these treatments. In particular, MDSC represent a potent population of suppressor cells that are elevated in many diVerent types of cancer, including neu positive mammary tumors in FVBN202 mice, and have been associated with suppression of T cell responses by multiple mechanisms. T regs were also reported to suppress anti-tumor immune responses. We looked at T regs in the blood, spleen, lymph nodes and the tumor site of FVBN202 mice and found no changes in the number of CD4+ CD25+ Foxp3+ T regs (data not shown). Since we wanted to determine whether MDSC could suppress robust T cell responses even against allogeneic antigen, we used FVB mice as donors of T cells. Although using such an allogeneic system will reduce clinical application of the proposed AIT regimen, failure of such eVector T cells in the rejection of MMC tumor cells attests to the strength of in vivo suppression by MDSC, and upon proving that MDSC depletion does indeed facilitate an otherwise ineVective AIT, we would next hope to use these procedures with the expansion of splenocytes from tumor sensitized FVBN202 mice. We also showed for the Wrst time that alternating gamma chain cytokine conditions are more eVective than IL-2 alone for the expansion of neu-speciWc anti-tumor eVector T cells. Having compared IL-2 with alternating gamma chain cytokines (IL-7 and IL-15 with a one-time dose of IL-2), we found that the latter was superior to the former in expanding T cells with a higher overall viability, as well as a higher proportion of eVector T cell phenotypes, which could readily exhibit anti-tumor activity. In fact, alternating gamma chain cytokine-expanded T cells showed a higher antitumor eYcacy than IL-2-expanded T cells, as evaluated by cytotoxicity assay in vitro. However, adoptive transfer of such eVector T cells did not overcome the pre-existing We have previously shown that these mice have increased levels of MDSC, even at the premalignant stage due to mammary hyperplasia [19, 24] . Interestingly, the combination of depleting MDSC in vivo with AIT using neu-speciWc T cells resulted in a robust tumor regression following AIT. Complete rejection of MMC tumors by the eVector T cells, however, was hindered by the fact that antibody-mediated MDSC depletion in FVBN202 mice was incomplete. This was due to increasing numbers of MDSC in tumor-bearing mice over time following the cessation of injection of anti-Gr1 antibody, as preliminary depletions (9 days after tumor challenge) were nearly 100% eVective (data not shown). To achieve MDSC depletion, we were not able to inject the rat anti-mouse Gr1 antibody more than six times because of its toxicity. Because of such limitations in the control of MDSC in vivo, we were able to perform prophylactic studies only. Therapeutic eYcacy of this strategy on established tumors remains to be determined using alternative drugs such as gemcitabine for selective elimination of MDSC [26] . Sporadic spontaneous tumor development after a long latency in FVBN202 mice makes it diYcult to test whether AIT combined with the inhibition of MDSC could also protect animals against spontaneous tumor development. Although other groups have reported the role of MDSC in suppression of anti-tumor T cell responses [3, 15, 16] , we report for the Wrst time that MDSC also suppress humoral immune responses following AIT so that depletion of MDSC in vivo restored anti-neu antibody responses in FVBN202 mice. This is very important because it has been reported that collaboration of humoral and cellular immune [17] and in cases of polymicrobial sepsis [9] . In order to further conWrm that failure of AIT to induce regression of MMC in FVBN202 mice was indeed due to inhibition of T cell function by MDSC, we performed in vitro assays to assess MDSC-mediated inhibition of T cell proliferation. Consistent with the fact that tumor-bearing animals exhibit about a fourfold increase of MDSC in the granulocyte region of their splenocytes [19] , total splenocytes from tumor-bearing mice showed a marked reduction in the number and percentage of proliferating T cells. SigniWcantly, depleting MDSC from the culture using either an anti-CD11b or an anti-Gr1 antibody caused the restoration of TCR-mediated T cell proliferation. These observations suggest that MDSC suppress TCR-induced proliferation of T cells.
The possible contact-dependent mechanism of T cell suppression by MDSC has been an area of some debate. Using diVerent tumor models, most groups have found suppression of T cells by MDSC to be mediated by soluble factors such as arginase-1, nitric oxide, reactive oxygen species and peroxynitrites [34, 39] . In particular, arginase-1 has been implicated in downregulation of the TCR zeta chain and the induction of this enzyme has been linked to tumor-derived soluble factors such as prostaglandin E2 as well as IL-4 and IL-13 [13, 34, 35] . Furthermore, arginine-depleted conditions can cause TCR zeta downregulation in the absence of cell-to-cell contact [35] . We were therefore surprised to see that in our model, cellto-cell contact was required for the suppression of T cell proliferation. Although other mechanisms may be involved in suppression of cytotoxic responses by T cells, we report here that no suppression of T cell proliferation was seen when MDSC were added to the top chamber of a transwell insert. Nagaraj et al. [31] have recently shown that direct cell-to-cell contact between CD8+ T cells and MDSC causes nitration of tyrosines in the TCR-CD8 complex, therefore disrupting binding of speciWc antigen-MHC class I complexes to the TCR's of OT-1 transgenic T cells. It is unclear, however, if the eVects of this nitration may be exaggerated due to transgenic expression of the TCR and what role this mechanism may play in a TCR non-transgenic model. Furthermore, Gabrilovich et al. [15] have reported that blocking the MHC class I molecules expressed on the surface of MDSC can reverse suppression of CD8+ T cells, which involved MDSC production of nitric oxide, but reported that these cells did not suppress CD4+ T cells responses towards MHC class II presented peptides. In 2000, Kusmartsev et al. showed inhibition of CD3/CD28 T cell activation by MDSC isolated from mice bearing MCA-26 colon carcinomas. However, this suppression was reversed by the addition of a superoxide dismutase mimetic and a nitric oxide synthase inhibitor and a possible role of contact was not investigated, and proliferation was not determined in separate populations of CD4+ and CD8+ T cells [27] . In contrast, we show here that MDSC from mice bearing HER2/ neu + mammary carcinomas inhibit the proliferation of both CD4+ and CD8+ T cells in contact-dependent manner. Therefore, although contact between MDSC and CD8+ T cells has been speculated to be important in inhibiting the IFN-response of CD8+ T cells towards speciWc peptide, we show here that contact is also necessary to inhibit CD3/CD28 T cell stimulation and can aVect the proliferation of both the CD4+ and CD8+ T cells populations.
Furthermore, we have shown that endogenous MDSC inhibit T cell proliferation in the splenocytes of tumor-bearing FVBVN202 mice. Therefore, it is likely that elevated levels of MDSC during the premalignant stage may generate an immunosuppressive microenvironment in these animals that could inhibit anti-tumor eYcacy of AIT. We have previously shown that increased MDSC in FVBN202 mice during the premalignant stage was associated with mammary gland hyperplasia, and this was correlated with the failure of pre-existing neu-speciWc immune responses to prevent spontaneous mammary carcinomas in these mice [19, 24] . We have also reported the existence of an immune suppressive microenvironment at the tumor lesions of FVBN202 mice, as evidenced by increased levels of IL-10, IL-10 receptor, SOCS-1, and SOCS-3 [44] . Such a microenvironment could then inhibit AIT unless it is combined with the depletion of MDSC, suggesting that MDSC may be the key cells initiating the cascade of events leading to tumor-speciWc immune suppression.
